Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

Trastuzumab is an iconic rationally designed targeted therapy for HER2-positive breast cancers. However, the low response rate and development of resistance call for novel approaches for the treatment of patients. Here, we report that concurrent targeting of tumor cells and activation of T cells in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang, Qingfei, Li, Shau-Hsuan, Wang, Hai, Xiao, Yi, Sahin, Ozgur, Brady, Samuel W., Li, Ping, Ge, Hailiang, Jaffee, Elizabeth M., Muller, William J., Hortobagyi, Gabriel N., Yu, Dihua
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556997/
https://ncbi.nlm.nih.gov/pubmed/22773664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-1339-T
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados